NATICK, Mass., June 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received FDA clearance to launch its Sterling™ Monorail® and Over-the-Wire Balloon Dilatation Catheter in the United States. The balloon catheters are available in a broad range of sizes, offering interventionalists superb clinical versatility. Both balloon catheter platforms are engineered for use in the renal and lower extremity arteries, as well as in dialysis fistula. In addition, the Sterling™ Monorail® Catheter received a specific indication for use in the carotid arteries as both a pre- and post-dilatation balloon.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060606/NYTU101 )

The Sterling Balloon Dilatation Catheter sets a new standard in peripheral angioplasty with its ultra-low profile balloon (4 French), designed to meet the challenges of the peripheral vasculature. "We have incorporated design elements from our industry-leading coronary balloon platform, the Maverick2™ Balloon Catheter," said John Pedersen, President of Boston Scientific's Peripheral Interventions Business. "Features such as the laser- formed, tapered tip are designed to facilitate crossing through the most challenging lesions, including tight stenosis and near occlusions."

The Sterling Balloon Dilatation Catheter represents a significant advance in peripheral balloon manufacturing and processing. Its refined profile is complemented by a balanced shaft featuring seamless transitions designed to offer clinicians enhanced trackability and powerful push when faced with traversing challenging anatomy.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

  CONTACT:  Milan Kofol
            508-650-8569
            Investor Relations
            Boston Scientific Corporation

            Eric Olson
            508-652-5367
            Media Relations
            Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, +1-508-650-8569, Investor Relations, or Eric
Olson, +1-508-652-5367, Media Relations, both for Boston Scientific
Corporation

Web site: http://www.bostonscientific.com/